long intergenic non-protein coding RNA 1701Genealiases: []
Q-omics provides the consensus-scored LINC01701 profile across patient tissues and cancer cell-line models. LINC01701 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC01701 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, LINC01701 RNA expression shows 5,074 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, HNSC, and UCEC as cancer lineages where LINC01701 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01701 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01701 survival associations across molecular data types. LINC01701 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01701 RNA expression–survival associations across cancer types. High LINC01701 expression shows unfavorable associations in ACC, LIHC, BRCA, GBM, KIRP and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC01701 RNA expression.
This table summarizes LINC01701 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01701. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01701 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, STAD, LUAD and LUSC. The HNSC box plot shows higher LINC01701 RNA expression in tumor versus normal tissue (log2 FC = +0.265, t-test p = .006).
This table shows molecular features associated with LINC01701 in patient tissues and cancer cell lines. In patient samples, LINC01701 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
